If you've ever had a bacterial infection like
staph or strep throat, your doctor may have prescribed penicillin. But if
you've had the flu or a common cold virus, penicillin won't work. That's
because antibacterials only kill bacteria, and both the flu and the common cold
are viruses.
So for
illnesses like the flu, doctors prescribe antiviral drugs, which target the
mechanisms that viruses use to reproduce.
"For
example, there are antivirals for the flu that interfere with the virus as it
tries to get out of its host cell," says science writer Carl Zimmer.
"So this molecule latches on to that particular protein that the virus
uses to escape, and interferes with it so that the virus is trapped
inside."
Zimmer's
latest piece for Wired magazine profiles the scientists who are developing
antiviral medications, and examines the new ways medicine is working to attack
viruses.
"There
are some really amazing antivirals that have been invented over the last 40
years," he says. "There are antivirals for herpes. There are
antivirals for HIV. ... Now, if you were to get Ebola and you tried to take HIV
drugs, they'd do you no good at all because that HIV drug only works for HIV.
It's a narrow-spectrum drug, and really, there are no broad-spectrum
antivirals, at this point."
Targeting Viruses Broadly
But
scientists are now working to create a "penicillin-like" drug that
will target viruses more broadly. In San Francisco, a company called Prosetta
is working on a drug that doesn't affect a virus directly. Instead, it works by
affecting the proteins that are naturally in cells that help viruses replicate.
"The
basic idea behind it is that viruses need help to build themselves," says
Zimmer. "What happens is quite amazing: [Viruses] get lots of different
proteins in our cells and cooperate to push their own proteins into place. And
so the viruses need these groups of host proteins to form."
Prosetta
created a drug that prevents the host proteins from performing their
cooperative jobs and helping the viruses out. Preliminary studies have shown
that targeting these host proteins — and not the virus itself — can stop Ebola,
influenza, rabies and other viruses.
Other
researchers are working to replace or help interferons, our body's own natural
virus-fighting system. Eleanor Fish, a researcher at the University of Toronto,
is heading a project to create synthetic interferon, in order to accelerate the
body's virus-fighting response.
"Today,
people with Hepatitis C can get interferon treatment, but it doesn't work all
that well. It has some benefit, but not as much as Eleanor Fish would
like," says Zimmer. "So she has been essentially tweaking the
interferon molecule to make it more effective, to make it last longer, to make
it safe and to make it cheap. Because what she wants to do is deploy interferon
all over the world where there isn't fancy refrigeration. She wants to help
people who are dealing with viruses in very remote places."
A third
approach, says Zimmer, involves creating an artificial protein that would latch
onto viruses and then instruct them to literally self-destruct. Spearheaded by
Todd Rider at MIT, the project has been tested in cells and in mice.
"Rider's
basically hot-wiring your cells so that as soon as they get infected by a
virus, that trips a switch," says Zimmer. "This doesn't exist
naturally, but if you were to take a pill, the thinking is, then this molecule
would go into your infected cells, and as soon as it detected the virus, it
would kill the infected cell, and you would recover from your disease."
But
successfully eradicating viruses may bring a host of other problems, says
Zimmer. He points to broad-spectrum antibiotics, which wipe out good bacteria
in addition to bad bacteria.
"Eventually
your body may recover, and it can take awhile, and there may be some bad
consequences of the antibiotics themselves," he says. "So it's going
to be interesting to see what happens in the future if we are, in fact,
knocking out lots of viruses. Because we don't understand the full ecology of
the viruses that get into our bodies."
There
are trillions of viruses that live in our bodies, even when we're not sick,
says Zimmer.
"Some
are harmful, some may not be harmful," he says. "Some may even help
us defend against other viruses. It's very complicated in there, and we don't
really understand it very well yet."
Transplanting
Gut Bacteria
Physicians
are now using bacteria to combat other diseases. Zimmer points to an example of
a patient infected with the Clostridium difficile bacteria, which causes severe
diarrhea and can frequently return, even when treated with antibiotics. The
patient was treated with a transfusion of gut microbials from a healthy
individual's fecal material to restore the bacterial flora in her intestinal
tract.
"Literally
two days later she started feeling better, and a couple weeks later, when they
went to sample the bacteria that was there, they couldn't find the C. difficile
anymore. It was just gone," he says. "The only thing they had done
was essentially restore her ecology, essentially like restoring a
wetland."
Zimmer
says fecal transplants have only been performed on patients when all other
options fail — but they are seemingly quite effective.
"The
problem is, as some other journalists have reported, is that the FDA has a very
difficult time figuring out how to come up with regulations for this," he
says. "Before it's going to become a widespread practice, the FDA is going
to have to move beyond its old paradigm of giving people regular drugs to being
able to give people tailored concoctions of living things — of bacteria, of
maybe even viruses — as medical treatments."
These
bacteria and viruses work in conjunction with other bacteria and viruses in the
body, but scientists still know very little about their mechanisms, says
Zimmer.
"There's
this whole ecosystem of interactions going on inside our own bodies that we do
not understand — barely at all," he says. "Scientists are just
starting to figure it out with very big projects where they're sequencing all
the genes these microbes have. But they're just at the beginning of understanding
it."
No comments:
Post a Comment